NCT07508488

Deucravacitinib in the Treatment of Cicatricial Alopecias

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Icahn School of Medicine at Mount Sinai · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a prospective, open-label clinical trial, in which all participants will be treated with deucravacitinib for 48 weeks. Approximately 20 participants will be enrolled: 10 Central Centrifugal Cicatricial Alopecia (CCCA) and 10 Frontal Fibrosing Alopecia (FFA). The study will take place at the Icahn School of Medicine at Mount Sinai (ISMMS). At the Baseline/Day 0 visit, participants will initiate treatment with deucravacitinib. All participants will receive deucravacitinib 12mg once-daily for 48 weeks. The treatment period will conclude at week 48.

Conditions

• Central Centrifugal Cicatricial Alopecia
• Frontal Fibrosing Alopecia

Interventions

Type	Name	Description
DRUG	Deucravacitinib	12mg once-daily oral treatment for 48 weeks.

Timeline

• Start date: 2026-04-01
• Primary completion: 2026-09-30
• Completion: 2027-01-21
• First posted: 2026-04-02
• Last updated: 2026-04-02

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study